Dr. Nicholas Restifo is a Cancer Immunotherapy Explorer who has dedicated over 30 years to developing immunotherapeutic treatments for cancer patients. He focuses on harnessing T cells to eradicate advanced and metastatic cancer. Dr. Restifo's educational background includes an MD from New York University and post-doctoral training at Memorial Sloan Kettering Cancer Center. Throughout his 31-year tenure at the National Cancer Institute, he made significant contributions to the field, such as defining the characteristics of effective anti-tumor T cells, identifying crucial gene expressions for successful immunotherapy, and studying mechanisms that regulate anti-tumor T cell activity. He has authored over 333 papers and numerous book chapters, impacting the landscape of cancer immunotherapy globally. Dr. Restifo has been recognized with various awards and was acknowledged by Thomson Reuters as one of the 'World's most influential scientific minds' in 2019.